BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lan Q, Xia S, Wang Q, Xu W, Huang H, Jiang S, Lu L. Development of oncolytic virotherapy: from genetic modification to combination therapy. Front Med 2020;14:160-84. [PMID: 32146606 DOI: 10.1007/s11684-020-0750-4] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 8.0] [Reference Citation Analysis]
Number Citing Articles
1 Chen X, Dai S, Zhan Y, Yang R, Chen D, Li Y, Zhou E, Dong R. Progress of oncolytic virotherapy for neuroblastoma. Front Pediatr 2022;10. [DOI: 10.3389/fped.2022.1055729] [Reference Citation Analysis]
2 Kong D, Yang Z, Li G, Wu Q, Gu Z, Wan D, Zhang Q, Zhang X, Cheng S, Liu B, Zhang K, Zhang W. SIRPα antibody combined with oncolytic virus OH2 protects against tumours by activating innate immunity and reprogramming the tumour immune microenvironment. BMC Med 2022;20:376. [PMID: 36310169 DOI: 10.1186/s12916-022-02574-z] [Reference Citation Analysis]
3 Schirrmacher V, van Gool S, Stuecker W. Counteracting Immunosuppression in the Tumor Microenvironment by Oncolytic Newcastle Disease Virus and Cellular Immunotherapy. IJMS 2022;23:13050. [DOI: 10.3390/ijms232113050] [Reference Citation Analysis]
4 Zou H, Mou X, Zhu B. Combining of Oncolytic Virotherapy and Other Immunotherapeutic Approaches in Cancer: A Powerful Functionalization Tactic. Global Challenges. [DOI: 10.1002/gch2.202200094] [Reference Citation Analysis]
5 Qi Z, Long X, Liu J, Cheng P. Glioblastoma microenvironment and its reprogramming by oncolytic virotherapy. Front Cell Neurosci 2022;16:819363. [DOI: 10.3389/fncel.2022.819363] [Reference Citation Analysis]
6 Garmaroudi GA, Karimi F, Naeini LG, Kokabian P, Givtaj N, Rehman MU. Therapeutic Efficacy of Oncolytic Viruses in Fighting Cancer: Recent Advances and Perspective. Oxidative Medicine and Cellular Longevity 2022;2022:1-14. [DOI: 10.1155/2022/3142306] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 Ren Y, Miao J, Wang Y, Fan Z, Kong X, Yang L, Cheng G. Oncolytic viruses combined with immune checkpoint therapy for colorectal cancer is a promising treatment option. Front Immunol 2022;13:961796. [DOI: 10.3389/fimmu.2022.961796] [Reference Citation Analysis]
8 Tang C, Li L, Mo T, Na J, Qian Z, Fan D, Sun X, Yao M, Pan L, Huang Y, Zhong L. Oncolytic viral vectors in the era of diversified cancer therapy: from preclinical to clinical. Clin Transl Oncol 2022. [PMID: 35612653 DOI: 10.1007/s12094-022-02830-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
9 Nikitina AS, Lipatova AV, Goncharov AO, Kliuchnikova AA, Pyatnitskiy MA, Kuznetsova KG, Hamad A, Vorobyev PO, Alekseeva ON, Mahmoud M, Shakiba Y, Anufrieva KS, Arapidi GP, Ivanov MV, Tarasova IA, Gorshkov MV, Chumakov PM, Moshkovskii SA. Multiomic Profiling Identified EGF Receptor Signaling as a Potential Inhibitor of Type I Interferon Response in Models of Oncolytic Therapy by Vesicular Stomatitis Virus. IJMS 2022;23:5244. [DOI: 10.3390/ijms23095244] [Reference Citation Analysis]
10 Melnikova EV, Rachinskaya OA, Merkulov VA. Advanced Therapy Medicines Based on Oncolytic Viruses (Part I: Development and Authorisation of Products in China). Vedomosti Nauchnogo tsentra ekspertizy sredstv meditsinskogo primeneniya 2021;11:148-159. [DOI: 10.30895/1991-2919-2021-11-148-159] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Zhou X, Zhao J, Zhang JV, Wu Y, Wang L, Chen X, Ji D, Zhou GG. Enhancing Therapeutic Efficacy of Oncolytic Herpes Simplex Virus with MEK Inhibitor Trametinib in Some BRAF or KRAS-Mutated Colorectal or Lung Carcinoma Models. Viruses 2021;13:1758. [PMID: 34578339 DOI: 10.3390/v13091758] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
12 Bahrololoumi Shapourabadi M, Momburg F, Roohvand F, Jarahian M, Mohajel N, Arashkia A, Hajari Taheri F, Abbasalipour M, Azadmanesh K. Bi/tri-specific antibodies (HN-Fc-CD16 and HN-Fc-IL-15-CD16) cross-linking natural killer (NK)-CD16 and Newcastle Disease Virus (NDV)-HN, enhanced NK activation for cancer immunotherapy. Int Immunopharmacol 2021;96:107762. [PMID: 34162140 DOI: 10.1016/j.intimp.2021.107762] [Reference Citation Analysis]
13 Abd-Aziz N, Poh CL. Development of oncolytic viruses for cancer therapy. Transl Res 2021:S1931-5244(21)00104-3. [PMID: 33905949 DOI: 10.1016/j.trsl.2021.04.008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
14 Lin W, Zhao Y, Zhong L. Current strategies of virotherapy in clinical trials for cancer treatment. J Med Virol 2021;93:4668-92. [PMID: 33738818 DOI: 10.1002/jmv.26947] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
15 Zhang J, Chen H, Chen C, Liu H, He Y, Zhao J, Yang P, Mao Q, Xia H. Systemic administration of mesenchymal stem cells loaded with a novel oncolytic adenovirus carrying IL-24/endostatin enhances glioma therapy. Cancer Lett 2021;509:26-38. [PMID: 33819529 DOI: 10.1016/j.canlet.2021.03.027] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
16 Jin KT, Du WL, Liu YY, Lan HR, Si JX, Mou XZ. Oncolytic Virotherapy in Solid Tumors: The Challenges and Achievements. Cancers (Basel) 2021;13:588. [PMID: 33546172 DOI: 10.3390/cancers13040588] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
17 Coënon L, Battistoni A, Poupée-Beaugé A, Germon S, Dimier-Poisson I. [Antitumoral microorganisms: The Swiss army knife of immunotherapy]. Med Sci (Paris) 2021;37:47-52. [PMID: 33492218 DOI: 10.1051/medsci/2020259] [Reference Citation Analysis]
18 Filin IY, Solovyeva VV, Kitaeva KV, Rutland CS, Rizvanov AA. Current Trends in Cancer Immunotherapy. Biomedicines 2020;8:E621. [PMID: 33348704 DOI: 10.3390/biomedicines8120621] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 8.5] [Reference Citation Analysis]
19 Kaygisiz K, Synatschke CV. Materials promoting viral gene delivery. Biomater Sci 2020;8:6113-56. [PMID: 33025967 DOI: 10.1039/d0bm01367f] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 12.0] [Reference Citation Analysis]
20 Hager S, Fittler FJ, Wagner E, Bros M. Nucleic Acid-Based Approaches for Tumor Therapy. Cells 2020;9:E2061. [PMID: 32917034 DOI: 10.3390/cells9092061] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 9.5] [Reference Citation Analysis]